Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2026-08-21 16:01:23 ET · period of report 2026-08-19 · accession 0001238303-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-21 16:01 | 2026-08-19 | REGN | LAROSA JOSEPH J | EVP GC, Secret | M - OptEx | $381.92 | +12.3K | 45.4K | +37% | +$4.69M |
| D | 2026-08-21 16:01 | 2026-08-19 | REGN | LAROSA JOSEPH J | EVP GC, Secret | F - Tax | $830.15 | -9,019 | 36.4K | -20% | -$7.49M |
| D | 2026-08-21 16:01 | 2026-08-19 | REGN | LAROSA JOSEPH J | EVP GC, Secret | M - OptEx | $0.00 | -12.3K | 12.3K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-19 | M | A | 12,282 | $381.92 | 45,392 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-19 | F | D | 9,019 | $830.15 | 36,373 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-08-19 | M | D | 12,282 | $0.00 | 12,283 | D | $381.92 · — to 2026-12-16 | 12,282 Common Stock | (F1) The stock option award vested in four equal annual installments, commencing one year after the date of grant. |